#xec — Public Fediverse posts

Humoral #immunity after #LP81 monovalent #vaccines against a broad range of #SARS-CoV-2 #variants including #XEC, LP.8.1, NB.1.8.1, #XFG, and #BA32, https://etidiohnew.blogspot.com/2026/01/humoral-immunity-after-lp81-monovalent.html

Here's the latest SARS-CoV-2 variant picture for Japan to mid-May. Regrettably, the sample volumes shrank from April onwards, so the picture is uncertain.

The NB.1.8.1 "Nimbus" variant grew during May to 33%. It is probably dominant by now over XEC.*, which was declining.

#SARSCoV2 #COVID19 #Japan #NB_1_8_1 #Nimbus #XEC
🧵

Here's the latest variant picture for the United Kingdom, to late April.

The LP.8.1.* variant has taken over dominance, growing steadily to around 57% frequency.

The XEC.* variant has fallen to around 25%.

#COVID19 #UK #XEC #LP_8_1
🧵

Here's the latest variant picture for Australia, to early May.

XEC.* has been dominant, but declined to around 32%.

LP.8.1.* has grown to 23%, and XDV.* (driven by NB.1.8.1) grew to 18%.

#COVID19 #Australia #XEC # LP_8_1 #NB_1_8_1 #XDV @auscovid19
🧵

Here's the latest variant picture for the United Kingdom, to late April.

The LP.8.1.* variant has taken over dominance, growing steadily to around 50% frequency.

The XEC.* variant has fallen to around 25%.

#COVID19 #UK #XEC #LP_8_1

Report link:
https://mike-honey.github.io/covid-19-genomes/output/Coronavirus%20-%20Genomic%20Sequencing%20-%20report%20UK.pdf

Here's the latest variant picture for Canada to late April.

The LP.8.1.* variant is now dominant, growing strongly to 56%.

The XEC.* variant has declined to around 18%.

#COVID19 #Canada #XEC #LP_8_1

Report link:
https://mike-honey.github.io/covid-19-genomes/output/Coronavirus%20-%20Genomic%20Sequencing%20-%20report%20Canada.pdf

Here's the latest variant picture for New Zealand, to early May.

DeFLuQE variants continue to dominate at around 40-80%

The XDV.* variant - driven by it’s latest sub-lineage NB.1.8.1 – is present, but only up to 11% so far.

#COVID19 #NZ #DeFLuQE #XEC #NB_1_8_1

Report link:
https://mike-honey.github.io/covid-19-genomes/output/Coronavirus%20-%20Genomic%20Sequencing%20-%20report%20NZ.pdf

Here's the latest variant picture for Australia, to mid-April.

XEC.* continues to dominate, but declined further to around 30%.

The next challenger now looks like LP.8.1.*, growing a bit faster to around 27%

XDV.*, driven by it’s latest sub-lineage NB.1.8.1, grew to around 19%, and it’s growth rate still looks the fastest.

#COVID19 #Australia #XEC # LP_8_1 #NB_1_8_1 #XDV @auscovid19
🧵

Here's the latest variant picture for Europe (excluding the UK), to mid-April.

The LP.8.1.* variant took over dominance, growing steadily to around 43% frequency.

The XEC.* variant fell to around 21%.

#COVID19 #EUR #XEC #LP_8_1
🧵

Here's the latest variant picture for the United Kingdom, to late April.

The LP.8.1.* variant has taken over dominance, growing steadily to around 50% frequency.

The XEC.* variant has fallen to around 25%.

#COVID19 #UK #XEC #LP_8_1
🧵
Report link:
https://mike-honey.github.io/covid-19-genomes/output/Coronavirus%20-%20Genomic%20Sequencing%20-%20report%20UK.pdf

Here's the latest variant picture for Canada to mid-April.

The LP.8.1.* variant is now dominant, growing strongly to 50%.

The XEC.* variant has declined to around 18%.

#COVID19 #Canada #XEC #LP_8_1

Report link:
https://mike-honey.github.io/covid-19-genomes/output/Coronavirus%20-%20Genomic%20Sequencing%20-%20report%20Canada.pdf

Here's the latest variant picture for New Zealand, to late April.

DeFLuQE variants continue to dominate at around 50-80%

The LP.8.1.* variant is not offering a sustained challenge.

This is a very unusual picture – in most places XEC.* and/or LP.8.1.* have become dominant.

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1

Report link:
https://mike-honey.github.io/covid-19-genomes/output/Coronavirus%20-%20Genomic%20Sequencing%20-%20report%20NZ.pdf

Here's the latest variant picture for Australia, to mid-April.

XEC.* continues to dominate, but declined quite sharply into around 40%.

The next challenger looks is XDV.*, driven by it’s latest sub-lineage NB.1.8.1, rising to 11%.

#COVID19 #Australia #XEC #NB_1_8_1 #XDV @auscovid19
🧵

Here's the latest variant picture for Australia, to mid-April.

XEC.* continues to dominate, but declined quite sharply in early April to around 40%.

LP.8.1.* variant is still struggling for traction below 20%.

The one to watch is XDV.*, driven by it’s latest sub-lineage NB.1.8.1, rising to 11%.

#COVID19 #Australia #XEC #LP_8_1 #NB_1_8_1 @auscovid19
🧵

With the LP.8.1.* variant on the way to dominance in most places, it is time to ponder which variant might drive the next wave.

The leading contenders at this point are LF.7.7.2, LF.7.9, NB.1.8.1, NY.9 (new), XEC.25.1, XFG and XFJ.

I show them here using a log scale, so you can compare their growth rates vs the most common LP.8.1.* sub-lineage: LP.8.1.1. Note the recent sample volumes are quite low, so the right side of this chart might not be a representative picture.

#COVID19 #LF_7_7_2 #LF_7_9 #NB_1_8_1 #XEC #XFG #XFJ
🧵

Here's the latest variant picture for Europe (excluding the UK), to mid-March.

The XEC.* variant remains dominant, but it has declined to around 35% frequency.

The LP.8.1.* variant grew to around 24%.

#COVID19 #EUR #XEC #LP_8_1
🧵

Here's the latest variant picture for Canada to mid-March.

The XEC.* variant is still dominant but has declined to 30%.

The LP.8.1.* variant is challenging at around 25%, probably overhauling the JN.1.* + DeFLuQE variants.

#COVID19 #Canada #XEC #LP_8_1
🧵

Here's the latest variant picture for the United States, to mid-March.

The LP.8.1.* variant growth resumed, up to around 54%.

The XEC.* variant has declined to around 18%.

#COVID19 #USA #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand, to late March.

DeFLuQE variants continue to dominate at around 40-60%

The LP.8.1.* variant bubbled up to 22%, before falling back in more recent samples.

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for Australia, to mid-March.

XEC.* continues to dominate, although fairly flat at around 50-60%.

The LP.8.1.* variant reached 16%, but then slumped to finish around 10%.

#COVID19 #Australia #XEC #LP_8_1 @auscovid19
🧵

Here's the latest variant picture with a global scope, to late March.

Growth of the LP.8.1.* variant resumed to around 38%, with the XEC.* variant declining to 29%.

#COVID19 #Global #XEC #LP_8_1
🧵

With the LP.8.1.* variant on the way to dominance in most places, it is time to ponder which variant might drive the next wave.

The leading contenders at this point are LF.7.7.2, LF.7.9, NB.1.8.1, XEC.25.1 XFH and (new) XFJ.

I show them here using a log scale, so you can compare their growth rates vs the most common LP.8.1.* sub-lineage: LP.8.1.1. There are more recent samples available, but the frequency analysis becomes increasingly distorted due to low volumes and patchy coverage.

#COVID19 #LF_7_7_2 #LF_7_9 #NB_1_8_1 #XEC #XFH #XFJ
🧵

Here's the latest variant picture for Europe (excluding the UK), to mid-March.

The XEC.* variant remains dominant, but it has declined to around 32% frequency.

The LP.8.1.* variant grew to around 22%.

#COVID19 #EUR #XEC #LP_8_1
🧵

Here's the latest variant picture for the United Kingdom, to late-March.

The XEC.* variant remains dominant, but it is generally declining to around 50% frequency.

Growth of the LP.8.1.* variant seemed to accelerate in the recent samples, to around 28%.

#COVID19 #UK #XEC #LP_8_1
🧵

Here's the latest variant picture for Canada to mid-March. Further samples been back-filled from Ontario, for a more complete picture.

The XEC.* variant is still dominant but has declined to 34%.

The LP.8.1.* variant is challenging at around 24%, probably overhauling the JN.1.* + DeFLuQE variants.

There might be some recent rebound in the FLuQE and FLiRT variants, as unfettered variant evolution continues.

#COVID19 #Canada #XEC #LP_8_1
🧵

Here's the latest variant picture for the United States, to mid-March.

The LP.8.1.* variant growth might be wobbling a bit, at around 47%.

The XEC.* variant has declined to around 21%.

#COVID19 #USA #XEC #LP_8_1
🧵

Here's the latest variant picture for Australia, to mid-March.

XEC.* continues to dominate, although fairly flat at around 50-60%.

The LP.8.1.* variant grew to around 17%, challenging the DeFLuQE variants as the new heir-apparent. It’s growth trajectory is quite slow.

#COVID19 #Australia #XEC #LP_8_1 @auscovid19
🧵

Here's the latest variant picture with a global scope, to mid- March.

Growth of the LP.8.1.* variant seemed to plateau at around 34%, with the XEC.* variant declining to 30%. Recent sample sizes are smaller so this might not be representative.

#COVID19 #Global #XEC #LP_8_1
🧵

With the LP.8.1.* variant on the way to dominance in most places, it is time to ponder which variant might drive the next wave.

The leading contenders at this point are LF.7.7.2, LF.7.9, NB.1.8.1, XEC.25.1 and XFH.

I show them here using a log scale, so you can compare their growth rates vs the most common LP.8.1.* sub-lineage: LP.8.1.1.

#COVID19 #LF_7_7_2 #LF_7_9 #NB_1_8_1 #XEC #XFH
🧵

Here's the latest variant picture for Europe (excluding the UK), to early March.

The XEC.* variant remains dominant, but it has declined to around 31% frequency.

The LP.8.1.* variant grew to around 23%.

Note the recent sample volumes are very low, so this might not be a representative picture.

#COVID19 #EUR #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand, to mid-March.

DeFLuQE variants continue to dominate, with the LP.8.1.* variant up to 18%, competing with XEC.*.

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand.

DeFLuQE variants continue to dominate, with the LP.8.1.* variant showing some strong recent growth to 24%, apparently overtaking XEC.*.

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand.

DeFLuQE variants continue to dominate, with XEC.* struggling to break above 40%.

This is quite an unusual picture as XEC.* is already dominant in most places.

The LP.8.1.* variant has mostly been below 10%.

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand.

DeFLuQE variants continue to dominate, with XEC.* seeming to be in decline.

This quite an unusual picture as XEC.* is already dominant in most places.

The LP.8.1.* variant grew to around 12%.

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand.

DeFLuQE variants continue to dominate, although XEC.* is now challenging.

This quite an unusual picture as XEC.* is already dominant in most places.

The new LP.8.1.* variant is present, but is still at low frequency (around 10%).

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand.

DeFLuQE variants continue to dominate, although XEC.* is now challenging.

This quite an unusual picture as XEC.* is already dominant in most places.

The new LP.8.1.* group of variants is present, but is still at low frequency (around 10%).

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand.

DeFLuQE variants continue to dominate, although XEC.* might be growing in recent samples. We can’t be certain with such small sample sizes.

This quite an unusual picture as XEC.* is already dominant in most places.

The new LP.8.1.* group of variants is present, but is still at low frequency (around 5%).

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

[Correspondence] #Antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against SARS-CoV-2 omicron subvariants including #JN1, #KP311, and #XEC https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00810-7/fulltext?rss=yes

Our data suggest that the receptor-binding domain of JN.1 S can effectively induce antiviral humoral immunity against JN.1 subvariants and XEC comparable to the full-length JN.1 S.

Here's the latest variant picture for Japan.

DeFLuQE variants have been rising to take over dominance from FLuQUE variants.

XEC.* grew to around 14%, but might have stalled there.

The recent rise in FLiRT variants is led by the LP.8.1 variant.

#COVID19 #Japan #DeFLuQE #FLiRT #FLuQE #XEC
🧵

Here's the latest variant picture for Canada.

DeFLuQE variants continue to dominate, although growth appears to have stalled.

XEC.* grew to around 26%.

#COVID19 #Canada #DeFLuQE #FLiRT #FLuQE #XEC
🧵

Robust #antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against a broad range of #SARS-CoV-2 #Omicron subvariants including #JN1, #KP311 and #XEC

Source: BioRxIV, AbstractAs of November 2024, SARS-CoV-2 Omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2), KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC, a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3), have been circulating in several countries. To control…

https://etidioh.wordpress.com/2024/11/21/robust-antiviral-humoral-immunity-induced-by-jn1-monovalent-mrna-vaccines-against-a-broad-range-of-sars-cov-2-omicron-subvariants-including-jn1-kp311-and-xec/

Here's the latest variant picture for Canada.

DeFLuQE variants continue to dominate, although growth appears to have stalled.

XEC.* grew to around 24%.

#COVID19 #Canada #DeFLuQE #FLiRT #FLuQE #XEC
🧵

Here's the latest variant picture for Europe (excluding the UK).

DeFLuQE variants continue to dominate, but they are now in decline.

XEC.* growth continued, to around 33%.

#COVID19 #EUR #DeFLuQE #FLiRT #FLuQE #XEC
🧵

Here's the latest variant picture for the United Kingdom.

DeFLuQE variants continue to dominate, however growth appears to have stalled.

XEC.* growth continued, to around 35%.

#COVID19 #UK #DeFLuQE #KP_3_1_1 #FLiRT #FLuQE #XEC
🧵

Here's the latest variant picture for Canada.

DeFLuQE variants continue to dominate, although growth appears to have stalled.

XEC.*, growth has also stalled – down slight to around 19%.

#COVID19 #Canada #DeFLuQE #FLiRT #FLuQE #XEC
🧵

Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC

Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…

https://etidioh.wordpress.com/2024/11/06/neutralizing-antibody-evasion-of-sars-cov-2-jn1-derivatives-kp3-kp311-lb1-and-xec/

Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC

Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…

https://etidioh.wordpress.com/2024/11/06/neutralizing-antibody-evasion-of-sars-cov-2-jn1-derivatives-kp3-kp311-lb1-and-xec/

Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC

Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…

https://etidioh.wordpress.com/2024/11/06/neutralizing-antibody-evasion-of-sars-cov-2-jn1-derivatives-kp3-kp311-lb1-and-xec/

Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC

Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…

https://etidioh.wordpress.com/2024/11/06/neutralizing-antibody-evasion-of-sars-cov-2-jn1-derivatives-kp3-kp311-lb1-and-xec/

Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC

Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…

https://etidioh.wordpress.com/2024/11/06/neutralizing-antibody-evasion-of-sars-cov-2-jn1-derivatives-kp3-kp311-lb1-and-xec/